[ACF] - Projects

  • D3Pharmachemistry (Tiziano Bandiera), D3Compunet (Andrea Cavalli), D3Validation (Angelo Reggiani), Molecular Modeling and Drug Discovery (Marco DeVivo): DMPK characterization of new chemical entities
  • Proteomics studies for RNA biology (Irene Bozzoni, Gian Gaetano Tartaglia, Stefano Gustincich)
  • Neurobiology of miRNAs (Davide De Pietri Tonelli): study of alterations in protein expression following cell treatment with selected miRNAs
  • Genetics of Cognition (Francesco Papaleo): brain proteomics of Lgdel mouse model of autism
  • Genetics and epigenetics of behavior (Valter Tucci): role of brain neurotransmitters in Praeder-Willis syndrome
  • CNCS (Alessandro Gozzi): PK studies on clozapine and other DREADD compounds
  • Nanotechnology for precision medicine (Paolo Decuzzi): mechanism of action of nanoparticles mediated drug delivery
  • Polymers and biomaterials (Nicole Tirelli): lipid composition of extracellular vesicles
  • Istituto Giannina Gaslini (Dr. Pedemonte): CFTR Proteomics to investigate the basic pathological mechanisms of cystic fibrosis
  • Università di Genova, DINOGMI (Dr.Nobbio): lipidomics investigation to understand demyelination and remyelination processes
  • Istituto Ortopedico Rizzoli (Dr. Avnet): lipidomics of bone tumour spheroids to uncover metastatic processes
  • Neuromed – Istituto Oncologico Mediterraneo (Dr. Maglione): lipidomic characterization of a Huntington’s disease mouse model
  • niversità di Genova (Prof. Ameri): doxorubicin quantification in cardiac fibroblasts.
  • Università di Milano (Prof. Aureli): expression proteomics on a model of neurodegeneration
  • H2020 GRAPHENE FLAGSHIP – CORE 3 (2020-2023)
    We are currently working on the properties of the biomolecular corona of graphene related materials and its role in the interaction with neuronal tissues.
    We have an ongoing research project on the investigation of the metabolome and proteome primary bronchial epithelial cells to uncover new potential target for cystic fibrosis.
    We recently patented a set of circulating biomarkers for AD and we are currently undertaking validation activities.